by Raynovich Rod | Jan 16, 2018 | Biopharmaceuticals
Update-1… January 17 Dow Rallies 300 Points Market returns to the momentum mode with tax reform theme, M&A and upbeat earnings. Apple (AAPL)was a driver as a potential job creator up 1.6% on repatriation of foreign cash and contributing $350B to economy. ...
by Raynovich Rod | Jan 15, 2018 | Biopharmaceuticals
Large Cap Biopharmaceuticals 2018 Performance after J.P.Morgan Healthcare Conference Here is an update of Large Cap Biopharmaceuticals Performance over the past 12 months. These numbers will be updated after all 2017 financials have been reported. Note that the IBB...
by Raynovich Rod | Jan 10, 2018 | Biopharmaceuticals
Sluggish Early Trading in Biotech Tracks NASDAQ Down 0.14%% Promising Year for M&A and Tax Cuts Improving Bottom Line There is a little follow-on to Tuesday’s rally bringing prices for major ETFs above where they were last week. The biotech screen reverted...
by Raynovich Rod | Jan 9, 2018 | Biopharmaceuticals
Weak Start for Biotech Stocks on 1/8/18-Red Screen Day Positive Updates on BIIB CELG GILD etc Biotech ETFs Firm Up about 1.5% Tuesday AM JPMorgan Healthcare Conference Biotech stocks abruptly sold off at the market open yesterday with the XBI down 2% to the $85.31...
by Raynovich Rod | Jan 2, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Rayno Life Science Portfolio
2/28/18 Update Tape looks sluggish at major resistance. Downgrade to HOLD on Celgene (CELG). Bad regulatory news on relapsing multiple sclerosis drug ozanimod. 2/2/18 Update After Sell-Off Cautious on Amgen (AMGN) after earnings release but looks better than the IBB...
by Raynovich Rod | Nov 29, 2017 | Biopharmaceuticals, Life Science ETF's and Mutual Funds, Macro
MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK...
by Raynovich Rod | Nov 20, 2017 | Biopharmaceuticals
11/29/17 Market Reversal in Early Trading 11:35a -FAANG sell-off Stocks show a rotation out of technology and into financials and cyclical consumer goods. XLK is down 2.2%, XLV up 0.66%, IBB up 0.42% with large caps holding. 11/28/17 Biotechs Treading Water But Many...
by Raynovich Rod | Nov 16, 2017 | Biopharmaceuticals
Biotech Correction: Sell-Off Has Reached 10% over Three Months Biotechs under pressure-has revenue growth slowed? Technicals-a break through bottom channel. Need a bounce today. Celgene is a bellwether. A buy in the $102 range. Biotech stocks have been weak since Q4...
by Raynovich Rod | Nov 13, 2017 | Biopharmaceuticals
Biotech Hangover from Earnings Clouds Outlook Healthcare sector (XLV) lagging technology (QQQ) and FAANG stocks. No earnings catalysts until Jan 2018 but Q4 has seen strong seasonality. Technicals rule as sellers predominate. Bull market is intact. On October 16 we...
by Raynovich Rod | Nov 6, 2017 | 2024 Rayno Biopharmaceuticals Portfolio
Update 11/8/17 …Per comments on Monday. Celgene (CELG) technicals are holding at $102-103 so we will add CELG to the Rayno Portfolio at a price of ~$102.5. The stock was battered on earnings news so we see good value and potential for long term growth. Forward...